

**8 AUGUST 2022**

**ASX Announcement**

**ADALTA SYDNEY INVESTOR BRIEFING INVITATION**

**MELBOURNE Australia, 8 August 2022:** AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased to invite shareholders and other investors to an in-person briefing session in Sydney on Thursday, 18 August 2022.

Following the release of AdAlta's Q4 FY22 quarterly report (ASX announcement: 25 July 2022), CEO and Managing Director, Dr Tim Oldham will discuss progress on the development of lead fibrosis asset AD-214 and other pipeline programs. Dr Oldham will also highlight the near-term milestones the Company is working toward through the current calendar half year and discuss recent progress towards partnering.

**Briefing details**

Date and time: Thursday 18 August from 12:15pm  
Venue: K&L Gates  
Level 31, 1 O'Connell St  
Sydney  
Format: Presentation, followed by Q&A, plus light sandwich lunch

**How to RSVP**

Shareholders and investors wishing to attend must RSVP by COB Tuesday, 15 August 2022 by phoning Phillipa Thorn on +61 404 839 848 or by emailing [phillipa.thorn@irdepartment.com.au](mailto:phillipa.thorn@irdepartment.com.au). Limited places are available, so early registration is recommended.

At the time of RSVP, please note your: name, email, contact number and advise of any special dietary requirements.

The AdAlta team looks forward to seeing those shareholders who are able to attend.

Authorised for lodgement by:

**Tim Oldham**  
**CEO and Managing Director**  
**August 2022**

## Notes to Editors

### About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in pre-clinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

### For more information, please contact:

#### Investors

Tim Oldham, CEO & Managing Director  
Tel: +61 403 446 665  
E: [t.oldham@adalta.com.au](mailto:t.oldham@adalta.com.au)

#### Media

IR Department  
Tel: +61 411 117 774  
E: [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)